Astrotech Corporation — Form 10-Q Summary
Period: The supplied filing is for the quarter ended March 31, 2017, Astrotech’s fiscal third quarter, and the nine months then ended. This differs from the request metadata of “2015 Q3.” Financial statements are unaudited; amounts below are in U.S. dollars.
Business context
Astrotech operates Astro Scientific, which includes chemical-analyzer developer 1st Detect and biotechnology venture Astrogenetix, and Astral, which provides film digitization, restoration, and HDR conversion. Most revenue came from fixed-price government-related subcontract work. Two customers accounted for virtually all nine-month revenue.
Financial results and liquidity
| Metric | Three months ended March 31, 2017 | Nine months ended March 31, 2017 |
|---|---|---|
| Revenue | $411,000 | $1.937 million |
| Gross profit / margin | $250,000 / 61% | $726,000 / 37% |
| Operating expenses | $3.194 million | $9.924 million |
| Operating loss | $2.944 million | $9.198 million |
| Net loss | $2.847 million | $8.968 million |
| Net loss attributable to Astrotech | $2.800 million ($0.14 per share) | $8.818 million ($0.43 per share) |
For the nine months, operating cash use was $6.457 million, investing activities provided $7.794 million, and financing activities used $1.283 million. Cash increased by $54,000 to $4.453 million. At March 31, cash plus short-term investments was $15.251 million; including long-term investments, cash and investments totaled about $17.4 million. Working capital was approximately $14.2 million. Total liabilities were $2.2 million, with no borrowings or interest paid reported. Management said liquidity was sufficient to fund expected needs through fiscal 2018.
Changes versus comparable periods
- Quarterly revenue rose $215,000 year over year; nine-month revenue rose $814,000. Management attributed the increase to activity on both major contracts, compared with revenue concentrated in one major contract in the prior-year quarter and period.
- Gross profit improved by $408,000 for the quarter and $589,000 for the nine months. Nine-month cost of revenue increased to $1.211 million, but revenue grew faster.
- Operating expenses declined $584,000 in the quarter and $401,000 for the nine months, primarily reflecting workforce reductions associated with 1st Detect’s realignment.
- Nine-month net loss narrowed to $8.968 million from $9.900 million. Cash used in operations declined to $6.457 million from $10.954 million.
- Total assets fell to $21.650 million from $30.523 million at June 30, 2016, chiefly alongside lower investment balances and operating cash consumption.
Outlook, risks, and unusual items
- No specific revenue or earnings guidance was provided. Management’s liquidity statement covers expected requirements through fiscal 2018 and is subject to capital needs, development progress, customer collections, and market conditions.
- Customer concentration is significant: the Department of Homeland Security Science and Technology Directorate partner represented 53% of nine-month sales and 87% of trade receivables; the Next Generation Chemical Detector partner represented 46% of sales. Dependence on government funding, contract timing, technical milestones, and customer demand are identified risks.
- Management reported that a partner did not plan to pursue the next phase of a chemical-detector program after Astrotech completed its portion of the contract.
- During the nine months, Astrotech repurchased 601,852 shares from its CEO for $975,000 and 192,000 shares from its CFO/COO related to tax withholding for $308,000. The prior share-repurchase program had ended in December 2016. Stock-based compensation was $1.035 million, including $778,000 for immediately vested stock.
- The company maintained a full valuation allowance against net deferred tax assets; the effective tax rate was approximately zero. No material pending legal proceedings or off-balance-sheet arrangements were reported.
Most important facts for investors to verify
- Whether the two principal government-related contracts generate follow-on work and whether customer concentration changes.
- Whether revenue growth and gross margins are sustainable given fixed-price contract estimates and delivery risks.
- Whether cash burn, investment liquidation, and capital requirements remain consistent with management’s stated fiscal 2018 liquidity runway.
- The terms, approvals, and rationale for related-party share repurchases and the impact of equity compensation on dilution.
- Whether the disclosed program transition, product commercialization plans, and segment progress support future revenue beyond current contracts.